GT 02037

Drug Profile

GT 02037

Alternative Names: GT02037

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmaspur Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Acromegaly

Most Recent Events

  • 10 Nov 2017 Pharmaspur plans a clinical trial for Chemotherapy-induced oral mucositis in healthy volunteers in Japan (UMIN000029929)
  • 07 Nov 2017 Pharmaspur completes enrolment in a clinical trial for Acromegaly (In volunteers) in Japan (UMIN000028302) prior to November 2017
  • 21 Jul 2017 Clinical trials in Acromegaly (In volunteers) in Japan (SC) (UMIN000028302)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top